Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAO-A Biomarker in Treatment Resistant Depression
NCT01031810Phase 4Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Nov 2009
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tranylcypromine in major depressive disorder (MDD), sponsored by New York State Psychiatric Institute. Started Nov 2009; status: terminated.
02
Drugs
tranylcypromine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01031810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031810.